メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
循環器内科学
藤田医科大学
医学部
概要
フィンガープリント
ネットワーク
プロファイル
(19)
研究成果
(486)
フィンガープリント
循環器内科学が活動している研究トピックを掘り下げます。これらのトピックラベルは、この組織のメンバーの研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Percutaneous Coronary Intervention
100%
Heart Failure
70%
Intravascular Ultrasound
60%
Acute Coronary Syndrome
56%
Myocardial Infarction
53%
Acute Heart Infarction
51%
Coronary Artery Disease
49%
Optical Coherence Tomography
46%
Computed Tomography Angiography
43%
Cardiovascular System
41%
Coronary Computed Tomography Angiography
37%
Atrial Fibrillation
33%
Fractional Flow Reserve
32%
Coronary Artery
27%
Statin
26%
Chronic Kidney Disease
26%
Antiplatelet
25%
Stenosis
25%
Everolimus
24%
Fulminant
24%
Myocarditis
24%
Revascularization
22%
Pitavastatin
21%
Drug-Eluting Stent
21%
Computer Assisted Tomography
21%
Odds Ratio
21%
Diabetes Mellitus
20%
Heart Muscle Injury
19%
Low Density Lipoprotein Cholesterol
19%
Stenting
19%
Hazard Ratio
18%
Major Adverse Cardiac Event
17%
Heart Muscle Ischemia
17%
Coronary Artery Obstruction
17%
Atorvastatin
16%
Brain Natriuretic Peptide
16%
Stent Thrombosis
16%
ST Elevation
16%
Percutaneous Transluminal Angioplasty
16%
Urinary System
15%
Coronary Angiography
15%
Creatinine
15%
Heart Transplantation
15%
Heart Death
15%
Echocardiography
14%
near Infrared Spectroscopy
14%
Atherosclerosis
14%
Heart Left Ventricle Ejection Fraction
14%
Rapamycin
13%
Acute Decompensated Heart Failure
13%
Fibrous Cap
13%
Bleeding
13%
In-Stent Restenosis
13%
Monotherapy
13%
Hospital Mortality
13%
Antithrombotic
13%
Risk Stratification
12%
C Reactive Protein
12%
Proportional Hazards Model
12%
Artery
12%
Multimodality Imaging
12%
Coronary Stenting
12%
Cardiac Sarcoidosis
12%
Mitral Insufficiency
12%
Extracorporeal Membrane Oxygenation
12%
Ejection Fraction
11%
Thrombosis
11%
Assisted Circulation
11%
Anticoagulation
11%
ST Segment Elevation Myocardial Infarction
11%
Prevalence
11%
T Wave Amplitude
11%
Glomerular Filtration Rate
10%
Angiography
10%
Randomized Controlled Trial
10%
Survival Rate
10%
Arteriosclerosis Obliterans
10%
Arm
10%
Non ST Segment Elevation Myocardial Infarction
10%
Primary Percutaneous Coronary Intervention
10%
Heart Failure with Reduced Ejection Fraction
10%
Rivaroxaban
10%
Catheter Ablation
10%
Cardiac Troponin
10%
Heart Muscle Revascularization
9%
Percutaneous Aortic Valve Replacement
9%
Apoplexy
9%
Biological Marker
9%
Frailty
9%
Ventricular Tachycardia
9%
Cardiovascular Disease
9%
Heart Function
9%
Ventricular Fibrillation
9%
Creatine Kinase
9%
Plaque Characterization
9%
Troponin I
9%
Thromboembolism
9%
Quantitative Coronary Angiography
8%
Prospective Cohort Study
8%
Troponin
8%
Pharmacology, Toxicology and Pharmaceutical Science
Coronary Artery Disease
68%
Acute Heart Infarction
67%
Heart Failure
66%
Atrial Fibrillation
56%
Pitavastatin
53%
Statin (Protein)
52%
Acute Coronary Syndrome
50%
Heart Infarction
42%
Low Density Lipoprotein Cholesterol
31%
Antiplatelet
29%
Cardiovascular Disease
25%
Bleeding
24%
Disease
23%
Inflammation
23%
Diabetes Mellitus
23%
Chronic Kidney Failure
22%
Brain Natriuretic Peptide
22%
C Reactive Protein
20%
Subarachnoid Hemorrhage
20%
Everolimus
20%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
20%
Heart Muscle Ischemia
19%
ST Segment Elevation Myocardial Infarction
17%
Coronary Artery Atherosclerosis
16%
Atorvastatin
16%
Hospital Mortality
16%
Heart Failure with Preserved Ejection Fraction
16%
Peripheral Occlusive Artery Disease
14%
Anticoagulant Agent
14%
Randomized Controlled Trial
14%
Combination Therapy
14%
Rivaroxaban
14%
Acute Heart Failure
13%
Frailty
13%
Creatinine
13%
Monotherapy
13%
Prevalence
13%
Major Adverse Cardiac Event
13%
Warfarin
12%
Ezetimibe
12%
Non Insulin Dependent Diabetes Mellitus
12%
Canagliflozin
12%
Azilsartan
12%
Thrombosis
11%
Biological Marker
11%
Icosapentaenoic Acid
11%
Heart Failure with Reduced Ejection Fraction
11%
Candesartan
11%
Acetylsalicylic Acid
11%
Atherosclerosis
10%
Coronavirinae
10%
Unstable Angina Pectoris
10%
Cause of Death
10%
High Density Lipoprotein Cholesterol
10%
Angiotensin Receptor Antagonist
10%
Antithrombotic Therapy
10%
Creatine Kinase
10%
Noradrenalin
9%
Non ST Segment Elevation Myocardial Infarction
9%
Troponin
8%
Omega-3 Fatty Acid
8%
Heart Disease
8%
Troponin T
8%
Hemodialysis
8%
Adiponectin
8%
Rapamycin
8%
Restenosis
8%
Macitentan
8%
In-Stent Restenosis
8%
Infrared Spectroscopy
8%
Midkine
8%
Acute Kidney Failure
8%
Fatty Acid Binding Protein
8%
Prasugrel
8%
Adverse Event
7%
Clinical Trial
7%
Stent Thrombosis
7%
Heart Death
7%
Apixaban
7%
Cardiogenic Shock
7%
Catecholamine
7%
Direct Oral Anticoagulant
7%
Stable Angina Pectoris
7%
Infarction
6%
Heart Muscle Injury
6%
Sodium Glucose Cotransporter 2 Inhibitor
6%
Pathophysiology
6%
ECG Abnormality
6%
Thromboembolism
5%
Dyslipidemia
5%
Clopidogrel
5%
Ischemic Heart Disease
5%
Prospective Cohort Study
5%
Adverse Outcome
5%
Antiapoptotic
5%
No Reflow Phenomenon
5%
Clotting Time
5%
Glimepiride
5%
Keyphrases
Acute Myocardial Infarction
22%
Myocardial Infarction
18%
Japanese Patients
17%
Coronary Computed Tomography Angiography
17%
Japan
16%
Percutaneous Coronary Intervention
15%
Acute Coronary Syndrome
12%
Fulminant Myocarditis
12%
Fractional Flow Reserve
12%
Heart Transplantation
11%
Everolimus-eluting Stent
10%
Sirolimus-eluting Stent
9%
ST-elevation Myocardial Infarction (STEMI)
9%
Risk Stratification
8%
Off-hours
8%
Macitentan
8%
Carotid Revascularization
8%
Monotherapy
8%
Chronic Coronary Syndrome
8%
Pitavastatin
8%
Atorvastatin
8%
Intensive Statin Therapy
8%
Minuet
8%
Optical Coherence Tomography
8%
Cardiac Intensive Care Unit
8%
Epicardial Adipose Tissue
8%
Periprocedural Myocardial Infarction
8%
Eicosapentaenoic Acid
8%
Genetic Risk
8%
Acute Kidney Injury
8%
Prasugrel
8%
Plain Old Balloon Angioplasty
7%
Computed Tomography Angiography
7%
Veno-venous Extracorporeal Membrane Oxygenation (VV-ECMO)
7%
High Bleeding Risk
7%
Dual Antiplatelet Therapy
6%
Intravascular Ultrasound
6%
Pullback
6%
Aspirin
6%
Stent
6%
Biodegradable Polymers
6%
Creatine Kinase
5%
Off-hour Presentation
5%
Pathological Findings
5%
Clinical Outcomes
5%
Bleeding Events
5%
Adverse Cardiac Events
5%
Cardiac Death
5%
Atrial Fibrillation
5%
Consecutive Patients
5%
Stent Thrombosis
5%
Universal Definition
5%
Plaque Progression
5%
Reduced Dose
5%
East Asian Patients
5%